KPC reports decline in revenue and net profit for nine months

KPC Pharmaceuticals, Inc. released its unaudited financial results for the nine months ended September 30, 2025, showing a notable decrease in revenue and net profit compared to the previous year. Revenue for the period stood at RMB4,751,206,077.58, down from RMB5,800,042,553.98 in the same period of 2024. Net profit also saw a decline, reaching RMB323,404,751.99, a decrease from RMB503,428,814.53 reported in 2024.

The company experienced a net decrease in cash and cash equivalents of RMB1,411,818,361.96, a significant shift from the RMB161,373,232.00 decrease in the prior year. Consequently, cash and cash equivalents at the end of the period were RMB722,106,049.81, compared to RMB1,205,460,153.12 at the end of September 2024.

As of September 30, 2025, total assets for KPC were RMB12,006,131,968.63, a slight reduction from RMB12,611,367,133.57 recorded on December 31, 2024. Total liabilities also decreased to RMB5,150,413,157.03 from RMB5,865,099,558.63, while owner's equity increased to RMB6,855,718,811.60 from RMB6,746,267,574.94 over the same period. These unaudited financials are prepared in accordance with PRC Generally Accepted Accounting Principles.